Decision: Favourable

Study Title:

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

  • NREC Code:

    22-NREC-CT-159

  • Decision:

    Favourable

  • Meeting Date:

    19/10/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Michael P. Keane

  • PI Institution:

    St Vincent's University Hospital

  • Sponsor:

    Boehringer Ingelheim International GmbH

Scroll to Top
Skip to content